SHR0302 and Steroid as First Line Therapy for Chronic GVHD
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of SHR0302 in combination with
Prednisone as first line therapy in patients with moderate to severe chronic
graft-versus-host disease (GVHD).
Phase:
Early Phase 1
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine